News

June 22, 2020June 22, 2020

Genetic Testing Often Worth the Wait for More Tailored Treatments, Study Says

News

Waiting for the results of genetic tests to begin treatment for acute myeloid leukemia (AML) might allow certain patients to benefit from more tailored therapies, according to a recent ... Read more

June 18, 2020June 18, 2020

FDA Approves Mylotarg as First-Line AML Treatment for Children

News

Mylotarg (gemtuzumab ozogamicin) has been approved for the first-line treatment of children, ages one month or older, who have acute myeloid leukemia (AML) positive for the CD33 protein, the ... Read more

June 15, 2020June 15, 2020

Moleculin Seeks Two More Test Sites in European Annamycin Trial

News

Despite disruptions from the COVID-19 pandemic, Moleculin Biotech is aiming to expand the number of sites for clinical trials of its annamycin chemotherapy for the treatment of acute myeloid ... Read more

June 11, 2020June 11, 2020

Protocol First Wins Funding for Beat AML Clinical Trial

News

Protocol First has received a funding commitment from The Leukemia & Lymphoma Society (LLS) to help advance the Beat AML Master Clinical Trial (Beat AML), which seeks to evaluate ... Read more

June 8, 2020June 8, 2020

Intellia Looking to Bring Its Potential T-cell Therapy for AML into Trials

News

Data from early studies suggest that Intellia Therapeutics‘s proprietary CRISPR/Cas9 technology can more effectively generate tumor targeting T-cells than conventional methods, and support testing NTLA-5001, the company’s engineered cell therapy ... Read more

June 4, 2020June 4, 2020

MacroGenics Plans Registration Study of Flotetuzumab for Hard-to-treat AML Patients

News

Following discussions with the U.S. Food and Drug Administration (FDA), MacroGenics is planning for a single-arm clinical trial that supports the approval of its investigational molecule flotetuzumab for the ... Read more

June 1, 2020June 1, 2020

FDA OKs Phase 1 Trial of Antibody, IO-202, to Treat Advanced AML and CMML

News

The U.S. Food and Drug Administration (FDA) has agreed to Immune-Onc Therapeutics launching a Phase 1 clinical trial of IO-202, its lead antibody treatment candidate, in patients with advanced acute myeloid ... Read more

May 28, 2020May 28, 2020

Venclexta Plus Vidaza Improves Survival for AML Patients, AbbVie Reports

News

First-line treatment with a combination of Venclexta (venetoclax) and Vidaza (azacitidine) significantly extended survival in people with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, as compared with Vidaza alone, ... Read more

May 21, 2020May 21, 2020

Annamycin Trial in Poland Permitted to Accelerate Dose Escalation in AML Patients

News

The Polish Department of Registration of Medicinal Products (URPL) has granted Moleculin Biotech permission to accelerate the dose-escalation portion of a Phase 1/2 clinical trial of Annamycin, which is ... Read more

May 21, 2020May 21, 2020

Video Games Connect Chronically Ill Children Isolated at Home, Hospital

cystic fibrosis, News, syndicated

Dara Riva always had a rule that her 10-year-old son could play video games only once a week. But then the COVID-19 pandemic struck, and her perspective changed. Riva’s ... Read more

Pin It on Pinterest